Baser O - Search Results

1

The Use of Decomposition Methods in Real-World Treatment Benefits Evaluation for Patients with Type 2 Diabetes Initiating Different Injectable Therapies: Findings from the INITIATOR Study.

Brekke L, Buysman E, Grabner M, Ke X, Xie L, Baser O, Wei W. Brekke L, et al. Among authors: baser o. Value Health. 2017 Dec;20(10):1252-1259. doi: 10.1016/j.jval.2017.05.019. Epub 2017 Jul 11. Value Health. 2017. PMID: 29241884 Free article.

2

The estimation power of alternative comorbidity indices.

Baser O, Palmer L, Stephenson J. Baser O, et al. Value Health. 2008 Sep-Oct;11(5):946-55. doi: 10.1111/j.1524-4733.2008.00343.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489502 Free article.

3

Too much ado about instrumental variable approach: is the cure worse than the disease?

Baser O. Baser O. Value Health. 2009 Nov-Dec;12(8):1201-9. doi: 10.1111/j.1524-4733.2009.00567.x. Epub 2009 May 29. Value Health. 2009. PMID: 19497084 Free article.

4

Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.

Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Baser O, et al. Adv Ther. 2010 Feb;27(2):94-104. doi: 10.1007/s12325-010-0009-6. Epub 2010 Mar 26. Adv Ther. 2010. PMID: 20352392

5

Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.

Baser O, Andrews LM, Wang L, Xie L. Baser O, et al. J Med Econ. 2011;14(5):576-83. doi: 10.3111/13696998.2011.596873. Epub 2011 Jul 6. J Med Econ. 2011. PMID: 21728914 Free article.

6

Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen versus exenatide BID.

Baser O, Wei W, Baser E, Xie L. Baser O, et al. Among authors: baser e. J Med Econ. 2011;14(6):673-80. doi: 10.3111/13696998.2011.605818. Epub 2011 Sep 5. J Med Econ. 2011. PMID: 21892858 Free article.

7

A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.

Xie L, Wei W, Pan C, Du J, Baser O. Xie L, et al. Among authors: baser o. Adv Ther. 2011 Nov;28(11):1000-11. doi: 10.1007/s12325-011-0074-5. Epub 2011 Oct 27. Adv Ther. 2011. PMID: 22038703

8

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.

Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Levin P, et al. Among authors: baser o. Curr Med Res Opin. 2012 Mar;28(3):439-46. doi: 10.1185/03007995.2012.654850. Epub 2012 Jan 23. Curr Med Res Opin. 2012. PMID: 22216894 Clinical Trial.

9

Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.

Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L. Baser O, et al. Curr Med Res Opin. 2012 Mar;28(3):419-28. doi: 10.1185/03007995.2011.628649. Epub 2012 Feb 24. Curr Med Res Opin. 2012. PMID: 22364568

10

Derivation of severity index for rheumatoid arthritis and its association with healthcare outcomes.

Baser O, Du J, Xie L, Wang H, Dysinger AH, Wang L. Baser O, et al. J Med Econ. 2012;15(5):918-24. doi: 10.3111/13696998.2012.688905. Epub 2012 May 18. J Med Econ. 2012. PMID: 22533525 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters